What to Expect From McKesson's Q1 2026 Earnings Report
/Mckesson%20Corporation%20logo%20on%20building-by%20JHVEPhoto%20via%20iStock.jpg)
Valued at a market cap of $89.5 billion, McKesson Corporation (MCK) is a healthcare services and information technology company headquartered in Irving, Texas. It provides pharmaceutical distribution, medical supplies, healthcare technology, and support services to pharmacies, hospitals, and biopharma companies. MCK is expected to announce its fiscal Q1 earnings for 2026 after the market closes on Wednesday, Aug. 6.
Ahead of this event, analysts expect this healthcare company to report a profit of $8.25 per share, up 4.7% from $7.88 per share in the year-ago quarter. The company has topped Wall Street’s earnings estimates in three of the last four quarters, while missing on another occasion. In Q4 2025, MCK’s EPS of $10.12 outpaced the forecasted figure by 3.2%.
For fiscal 2026, analysts expect McKesson to report a profit of $37.25 per share, up 12.7% from $33.05 per share in fiscal 2025. Furthermore, its EPS is expected to grow 12.1% year-over-year to $41.76 in fiscal 2027.
Shares of MCK have rallied 22.6% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 10.5% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 10.4% decline over the same time frame.
On May 8, McKesson delivered mixed Q4 results, and its shares closed up marginally in the following trading session. The company’s total revenue improved 18.9% year-over-year to $90.8 billion, driven by strength in its pharmaceutical distribution division, expansion of its oncology platform, and continued growth in biopharma solutions. However, the top-line figure fell short of the consensus expectations by 3.1%. Nonetheless, due to higher revenue, lower tax rate, and strong operational growth across the business, MCK’s adjusted EPS of $10.12 advanced 63.8% from the year-ago quarter and exceeded the consensus estimates by 3.2%.
Wall Street analysts are highly optimistic about MCK’s stock, with a "Strong Buy" rating overall. Among 16 analysts covering the stock, 12 recommend "Strong Buy" and four suggest "Hold.” The mean price target for MCK is $785.47, implying a 9.7% premium from the current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.